Showing 3351-3360 of 6040 results for "".
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adult
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial&nbs
- Positive Results Reported From Delgocitinib CHE Trial in Chinahttps://practicaldermatology.com/news/Positive-Results-Reported-Delgocitinib-CHE-Trial-China/2471379/Positive results were announced for the primary endpoint from the double-blind treatment period of the DELTA China phase 3 clinical trial with Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adults and adolescents (aged 12 a
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-w